Seelos therapeutics, inc. releases letter to its stockholders

New york , dec. 22, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released a letter to its stockholders from raj mehra, ph.d., chairman and chief executive officer of seelos, the text of which is copied below.

SEEL Ratings Summary

SEEL Quant Ranking